AU2016219917B2 - Methods, compositions, and kits for treatment of cancer - Google Patents

Methods, compositions, and kits for treatment of cancer Download PDF

Info

Publication number
AU2016219917B2
AU2016219917B2 AU2016219917A AU2016219917A AU2016219917B2 AU 2016219917 B2 AU2016219917 B2 AU 2016219917B2 AU 2016219917 A AU2016219917 A AU 2016219917A AU 2016219917 A AU2016219917 A AU 2016219917A AU 2016219917 B2 AU2016219917 B2 AU 2016219917B2
Authority
AU
Australia
Prior art keywords
inhibitor
fgfr3
seq
antagonistic
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016219917A
Other languages
English (en)
Other versions
AU2016219917A1 (en
Inventor
Jocelyn Holash
Stephen Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Pharmaceuticals Inc
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of AU2016219917A1 publication Critical patent/AU2016219917A1/en
Assigned to Rainier Therapeutics, Inc. reassignment Rainier Therapeutics, Inc. Alteration of Name(s) of Applicant(s) under S113 Assignors: BIOCLIN THERAPEUTICS, INC.
Assigned to Fusion Pharmaceuticals Inc. reassignment Fusion Pharmaceuticals Inc. Request for Assignment Assignors: Rainier Therapeutics, Inc.
Application granted granted Critical
Publication of AU2016219917B2 publication Critical patent/AU2016219917B2/en
Priority to AU2022200196A priority Critical patent/AU2022200196B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016219917A 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer Active AU2016219917B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200196A AU2022200196B2 (en) 2015-02-19 2022-01-13 Methods, compositions, and kits for treatment of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562118350P 2015-02-19 2015-02-19
US62/118,350 2015-02-19
US201562150235P 2015-04-20 2015-04-20
US62/150,235 2015-04-20
PCT/US2016/018634 WO2016134234A1 (en) 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200196A Division AU2022200196B2 (en) 2015-02-19 2022-01-13 Methods, compositions, and kits for treatment of cancer

Publications (2)

Publication Number Publication Date
AU2016219917A1 AU2016219917A1 (en) 2017-09-07
AU2016219917B2 true AU2016219917B2 (en) 2021-12-16

Family

ID=56689191

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016219917A Active AU2016219917B2 (en) 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer
AU2022200196A Expired - Fee Related AU2022200196B2 (en) 2015-02-19 2022-01-13 Methods, compositions, and kits for treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200196A Expired - Fee Related AU2022200196B2 (en) 2015-02-19 2022-01-13 Methods, compositions, and kits for treatment of cancer

Country Status (12)

Country Link
US (1) US20160243228A1 (cg-RX-API-DMAC7.html)
EP (1) EP3258966A4 (cg-RX-API-DMAC7.html)
JP (2) JP6774421B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170137717A (cg-RX-API-DMAC7.html)
CN (1) CN107635583A (cg-RX-API-DMAC7.html)
AU (2) AU2016219917B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017017700A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976638A1 (cg-RX-API-DMAC7.html)
IL (1) IL253979B (cg-RX-API-DMAC7.html)
MX (1) MX2017010595A (cg-RX-API-DMAC7.html)
SG (1) SG11201706727XA (cg-RX-API-DMAC7.html)
WO (1) WO2016134234A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP6898919B2 (ja) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN115177619A (zh) 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
KR20200026787A (ko) * 2017-02-06 2020-03-11 레이니어 테라퓨틱스, 인크. 암 치료를 위한 방법, 조성물, 및 키트
CN108440673B (zh) * 2018-04-08 2021-08-17 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
US20200277387A1 (en) * 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer
CN113710244A (zh) * 2019-06-03 2021-11-26 融合制药公司 用于治疗癌症的方法和组合物
EP4034118A1 (en) * 2019-09-26 2022-08-03 Janssen Pharmaceutica NV Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
BR112022019226A2 (pt) * 2020-03-23 2022-11-08 Fusion Pharmaceuticals Inc Radioimunoconjugados direcionados a fgfr3 e usos dos mesmos
US11505611B2 (en) 2020-08-21 2022-11-22 Genzyme Corporation FGFR3 antibodies and methods of use
TW202233185A (zh) * 2020-10-28 2022-09-01 日商衛材R&D企管股份有限公司 腫瘤治療用醫藥組合物
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048026A2 (en) * 2008-10-20 2010-04-29 Imclone Llc Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120553A1 (es) * 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
US8754114B2 (en) * 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112015001724A2 (pt) * 2012-07-27 2018-04-03 Genentech Inc métodos de tratamento de condições relacionadas a fgfr3
MX384142B (es) * 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048026A2 (en) * 2008-10-20 2010-04-29 Imclone Llc Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Also Published As

Publication number Publication date
IL253979B (en) 2021-06-30
AU2022200196B2 (en) 2025-04-10
BR112017017700A2 (pt) 2018-07-31
US20160243228A1 (en) 2016-08-25
JP6774421B2 (ja) 2020-10-21
JP2018507220A (ja) 2018-03-15
CN107635583A (zh) 2018-01-26
IL253979A0 (en) 2017-10-31
MX2017010595A (es) 2018-11-12
JP7122357B2 (ja) 2022-08-19
EP3258966A1 (en) 2017-12-27
SG11201706727XA (en) 2017-09-28
JP2021020909A (ja) 2021-02-18
WO2016134234A1 (en) 2016-08-25
NZ735243A (en) 2024-11-29
AU2022200196A1 (en) 2022-02-10
EP3258966A4 (en) 2018-07-25
KR20170137717A (ko) 2017-12-13
CA2976638A1 (en) 2016-08-25
AU2016219917A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
AU2022200196B2 (en) Methods, compositions, and kits for treatment of cancer
JP7507209B2 (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
KR102870759B1 (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
GB2531094A (en) Anti-B7-H1 and Anti-CTLA-4 antibodies for treating non-small cell lung cancer
CN104470949A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP3307778A1 (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
KR20160108566A (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr 억제제의 조합
KR20160044480A (ko) Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
WO2015166484A1 (en) Humanized antibodies against ceacam1
CA3048916A1 (en) Methods, compositions, and kits for treatment of cancer
US20230250182A1 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
CN116406288A (zh) 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法
KR20250135324A (ko) 병용 요법을 위한 방법 및 조성물
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
AU2024277733A1 (en) Methods of treating cancer with anti-mica/b antibodies

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: RAINIER THERAPEUTICS, INC.

Free format text: FORMER NAME(S): BIOCLIN THERAPEUTICS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: FUSION PHARMACEUTICALS INC.

Free format text: FORMER APPLICANT(S): RAINIER THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)